Status:
COMPLETED
Radium-223 Dichloride Long-term Follow-up Program
Lead Sponsor:
Bayer
Conditions:
Neoplasm Metastasis / Bone and Bones
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.
Detailed Description
This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives a...
Eligibility Criteria
Inclusion
- Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial
Exclusion
- Not applicable to this follow up study
Key Trial Info
Start Date :
December 18 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT02312960
Start Date
December 18 2014
End Date
January 31 2024
Last Update
March 25 2025
Active Locations (117)
Enter a location and click search to find clinical trials sorted by distance.
1
Anchorage, Alaska, United States, 99503
2
Tucson, Arizona, United States, 85704
3
Plantation, Florida, United States, 33324
4
Indianapolis, Indiana, United States, 46202